De Ciuceis Carolina, Savoia Carmine, Arrabito Emanuele, Porteri Enzo, Mazza Monica, Rossini Claudia, Duse Sarah, Semeraro Francesco, Agabiti Rosei Claudia, Alonzo Alessandro, Sada Lidia, La Boria Elisa, Sarkar Annamaria, Petroboni Beatrice, Mercantini Paolo, Volpe Massimo, Rizzoni Damiano, Agabiti Rosei Enrico
From the Clinica Medica, Department of Clinical and Experimental Sciences (C.D.C., E.P., M.M., C.R., C.A.R., E.L.B., A.S., B.P., D.R., E.A.R.) and Division of Ophthalmology (S.D., F.S.), University of Brescia, Brescia, Italy; and Division of Cardiology, Department of Clinical and Molecular Medicine (C.S., E.A., A.A., L.S., M.V.) and Surgical Department of Clinical Sciences (P.M.), Biomedical Technologies and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Hypertension. 2014 Oct;64(4):717-24. doi: 10.1161/HYPERTENSIONAHA.114.03380. Epub 2014 Jun 30.
Structural alterations of subcutaneous small-resistance arteries are associated with a worse clinical prognosis in hypertension and non-insulin-dependent diabetes mellitus. The effects of the direct renin inhibitor aliskiren on microvascular structure were never previously evaluated. Therefore, we investigated the effects of aliskiren in comparison with those of an extensively used angiotensin-converting enzyme inhibitor, ramipril, on peripheral subcutaneous small-resistance artery morphology, retinal arteriolar structure, and capillary density in a population of patients with non-insulin-dependent diabetes mellitus. Sixteen patients with mild essential hypertension and with a previous diagnosis of non-insulin-dependent diabetes mellitus were included in the study. Patients were then randomized to 1 of the 2 active treatments (aliskiren 150 mg once daily, n=9; or ramipril 5 mg once daily, n=7). Each patient underwent a biopsy of the subcutaneous fat from the gluteal region, an evaluation of retinal artery morphology (scanning laser Doppler flowmetry), and capillary density (capillaroscopy), at baseline and after 1 year of treatment. Subcutaneous small arteries were dissected and mounted on a pressurized micromyograph, and the media-to-lumen ratio was evaluated. A similar office blood pressure-lowering effect and a similar reduction of the wall-to-lumen ratio of retinal arterioles were observed with the 2 drugs. Aliskiren significantly reduced media-to-lumen ratio of subcutaneous small-resistance arteries, whereas ramipril-induced reduction of media to lumen ratio was not statistically significant. No relevant effect on capillary density was observed. In conclusion, treatment with aliskiren or ramipril was associated with a correction of microvascular structural alterations in patients with non-insulin-dependent diabetes mellitus.
皮下小阻力动脉的结构改变与高血压和非胰岛素依赖型糖尿病患者较差的临床预后相关。此前从未评估过直接肾素抑制剂阿利吉仑对微血管结构的影响。因此,我们在一群非胰岛素依赖型糖尿病患者中,研究了阿利吉仑与广泛使用的血管紧张素转换酶抑制剂雷米普利相比,对外周皮下小阻力动脉形态、视网膜小动脉结构和毛细血管密度的影响。16例轻度原发性高血压且既往诊断为非胰岛素依赖型糖尿病的患者纳入研究。然后将患者随机分为2种活性治疗中的1种(阿利吉仑150 mg每日1次,n = 9;或雷米普利5 mg每日1次,n = 7)。每位患者在基线和治疗1年后,接受臀区皮下脂肪活检、视网膜动脉形态评估(扫描激光多普勒血流仪)和毛细血管密度评估(毛细血管显微镜检查)。解剖皮下小动脉并安装在加压微血管张力测定仪上,评估中膜与管腔比值。两种药物均观察到相似的诊室血压降低效果和相似的视网膜小动脉壁腔比值降低。阿利吉仑显著降低了皮下小阻力动脉的中膜与管腔比值,而雷米普利引起的中膜与管腔比值降低无统计学意义。未观察到对毛细血管密度的相关影响。总之,阿利吉仑或雷米普利治疗与非胰岛素依赖型糖尿病患者微血管结构改变的纠正相关。